Search in:

Expert Opinion on Therapeutic Targets Volume 15, 2011 - Issue 3

Submit an article Journal homepage

621

Views

CrossRef citations to date

Altmetric

Key Paper Evaluation

Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease?

Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693–703

Sabina Antonela Antoniu University of Medicine and Pharmacy “Gr.T.Popa” Iasi, Pulmonary Disease University Hospital, Department of Internal Medicine II-Pulmonary Disease, 30 Dr I Cihac Str, 700115 Iasi, Romania +40 232 239408; +40 232 270918; [email protected]

, MD PhD

Pages 351-353 | Published online: 05 Jan 2011

Cite this article
https://doi.org/10.1517/14728222.2011.550880

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Citations (24)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (24)

Xiaoyun Lu. 2023. Privileged Scaffolds in Drug Discovery. Privileged Scaffolds in Drug Discovery 391 404 .

Xiangxiang Jiang, Na Qin, Tingting Hua, Xiaoxia Wei, Yuancheng Li, Congcong Chen, Linnan Gong, Su Liu, Cheng Wang, Rong Yin, Yue Jiang, Juncheng Dai, Lin Xu, Hongbing Shen & Hongxia Ma. (2022) Functional characterization and clinical significance of super‐enhancers in lung adenocarcinoma. Molecular Carcinogenesis 61:8, pages 776-786.
Crossref

Shaowen Xie, Yuan Sun, Yulin Liu, Xinnan Li, Xinuo Li, Wenyi Zhong, Feiyan Zhan, Jingjie Zhu, Hong Yao, Dong-Hua Yang, Zhe-Sheng Chen, Jinyi Xu & Shengtao Xu. (2021) Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK). Journal of Medicinal Chemistry 64:13, pages 9120-9140.
Crossref

Dung-Tsa Chen, Wenyaw Chan, Zachary J. Thompson, Ram Thapa, Amer A. Beg, Andreas N. Saltos, Alberto A. Chiappori, Jhanelle E. Gray, Eric B. Haura, Trevor A. Rose & Ben Creelan. (2021) Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer. PLOS ONE 16:7, pages e0252041.
Crossref

Saki Manabe, Rika Kasajima, Shuji Murakami, Yohei Miyagi, Tomoyuki Yokose, Tetsuro Kondo, Haruhiro Saito, Hiroyuki Ito, Takeshi Kaneko & Kouzo Yamada. (2020) Analysis of targeted somatic mutations in pleomorphic carcinoma of the lung using next‐generation sequencing technique . Thoracic Cancer 11:8, pages 2262-2269.
Crossref

Bayu Tri Murti, Athika Darumas Putri, Lalu Muhammad Irham, Dyah Aryani Perwitasari, Chien-Ming Hsieh, Po-Kang Yang, Suvardhan Kanchi & Myalowenkosi Sabela. 2020. Nanomaterials in Diagnostic Tools and Devices. Nanomaterials in Diagnostic Tools and Devices 351 393 .

Verena Schildgen & Oliver Schildgen. (2019) The lonely driver or the orchestra of mutations? How next generation sequencing datasets contradict the concept of single driver checkpoint mutations in solid tumours – NSCLC as a scholarly example. Seminars in Cancer Biology 58, pages 22-28.
Crossref

Saphy Sharda, Ravina Khandelwal, Ritu Adhikary, Diksha Sharma, Manisha Majhi, Tajamul Hussain, Anuraj Nayarisseri & Sanjeev Kumar Singh. (2019) A Computer - Aided Drug Designing for Pharmacological Inhibition of Mutant ALK for the Treatment of Non-small Cell Lung Cancer. Current Topics in Medicinal Chemistry 19:13, pages 1129-1144.
Crossref

Jee-Eun Jang, Hwang-Phill Kim, Sae-Won Han, Hoon Jang, Si-Hyun Lee, Sang-Hyun Song, Duhee Bang & Tae-You Kim. (2019) NFATC3–PLA2G15 Fusion Transcript Identified by RNA Sequencing Promotes Tumor Invasion and Proliferation in Colorectal Cancer Cell Lines. Cancer Research and Treatment 51:1, pages 391-401.
Crossref

Jason N Rosenbaum, Ryan Bloom, Jason T Forys, Jeff Hiken, Jon R Armstrong, Julie Branson, Samantha McNulty, Priya D Velu, Kymberlie Pepin, Haley Abel, Catherine E Cottrell, John D Pfeifer, Shashikant Kulkarni, Ramaswamy Govindan, Eric Q Konnick, Christina M Lockwood & Eric J Duncavage. (2018) Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer. Modern Pathology 31:5, pages 791-808.
Crossref

Amanda Craig. (2017) Personalised Medicine with Companion Diagnostics: The Intercept of Medicines and Medical Devices in the Regulatory Landscape. EMJ Innovations, pages 47-53.
Crossref

H. Louise Lund, Curtis B. Hughesman, Kareem Fakhfakh, Kelly McNeil, Shahira Clemens, Kimberly Hocken, Ryan Pettersson, Aly Karsan, Leonard J. Foster & Charles Haynes. (2016) Initial Diagnosis of ALK -Positive Non-Small-Cell Lung Cancer Based on Analysis of ALK Status Utilizing Droplet Digital PCR . Analytical Chemistry 88:9, pages 4879-4885.
Crossref

Wentao Li, Lap Ah Tse & Feng Wang. (2015) Prognostic value of estrogen receptors mRNA expression in non-small cell lung cancer: A systematic review and meta-analysis. Steroids 104, pages 129-136.
Crossref

. (2015) Singapore Cancer Network (SCAN) Guidelines for the Use of Systemic Therapy in Advanced Non-Small Cell Lung Cancer. Annals of the Academy of Medicine, Singapore 44:10, pages 449-462.
Crossref

Lan-Ying Gou, Fei-Yu Niu, Yi-Long Wu & Wen-Zhao Zhong. (2015) Differences in driver genes between smoking-related and non-smoking-related lung cancer in the Chinese population. Cancer 121:S17, pages 3069-3079.
Crossref

Tony J. C. Wang, Shumaila Saad, Yasir H. Qureshi, Ashish Jani, Tavish Nanda, Andrew M. Yaeh, Tzlil Rozenblat, Michael B. Sisti, Jeffrey N. Bruce, Guy M. McKhann, Jeraldine Lesser, Balazs Halmos, Mark B. Stoopler, Andrew B. Lassman, Simon K. Cheng & Steven R. Isaacson. (2015) Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?. Neuro-Oncology 17:7, pages 1022-1028.
Crossref

Sumanta Kumar Pal, David Y. Josephson, Przemyslaw Twardowski & David I. Quinn. 2015. Kidney Cancer. Kidney Cancer 385 402 .

Jiandong Wang, Qin Shen, Qunli Shi, Bo Yu, Xuan Wang, Kai Cheng, Guangming Lu & Xiaojun Zhou. (2014) Detection of ALK protein expression in lung squamous cell carcinomas by immunohistochemistry. Journal of Experimental & Clinical Cancer Research 33:1.
Crossref

Richard M. Neve, Lisa D. Belmont, Richard Bourgon, Marie Evangelista, Xiaodong Huang, Maike Schmidt, Robert L. Yauch & Jeffrey Settleman. 2013. Medicinal Chemistry Approaches to Personalized Medicine. Medicinal Chemistry Approaches to Personalized Medicine 21 70 .

Nicla Borrelli, Riccardo Giannini, Agnese Proietti, Greta Alì, Serena Pelliccioni, Cristina Niccoli, Marco Lucchi, Franca Melfi, Alfredo Mussi, Fulvio Basolo & Gabriella Fontanini. (2013) KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung. Lung Cancer 81:3, pages 377-381.
Crossref

June Koo Lee, Heae Surng Park, Dong‐Wan Kim, Kimary Kulig, Tae Min Kim, Se‐Hoon Lee, Yoon‐Kyung Jeon, Doo Hyun Chung, Dae Seog Heo, Woo‐Ho Kim & Yung‐Jue Bang. (2011) Comparative analyses of overall survival in patients with anaplastic lymphoma kinase‐positive and matched wild‐type advanced nonsmall cell lung cancer. Cancer 118:14, pages 3579-3586.
Crossref

Sumanta Kumar Pal, David Y. Josephson, Przemyslaw Twardowski & David I. Quinn. 2012. Kidney Cancer. Kidney Cancer 285 301 .

Antonio Rossi, Domenico Galetta, Luca Bottiglieri, Viviana Stufano & Massimo Barberis. (2011) Evaluation of ALK Gene Status in Primary Lung Adenocarcinoma and Matched Metastases. Journal of Thoracic Oncology 6:6, pages 1146.
Crossref

Han Chong Toh. (2011) World Cancer Day 2011 – A World without Cancer One Day?. Annals of the Academy of Medicine, Singapore 40:2, pages 65-66.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease?

Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693–703

Articles from other publishers (24)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease?

Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693–703

Citations (24)

Articles from other publishers (24)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date